Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VulVaccin study
NL-OMON60933Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in HPV-related vulvar intraepithelial neoplasia comparing Gardasil 9 plus standard vulvar HSIL treatment with Placebo plus standard vulvar HSIL treatment (2 arms). Primary endpoint: Clinical recurrence of vulvar HSIL up to 24 months. Started Mar 2024; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
HPV-related vulvar intraepithelial neoplasia
Beyond the preview
Go deeper on NL-OMON60933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60933.